| Objective: To evaluate the efficacy of Chinese patent medicine in the treatment of benign prostatic hyperplasia(BPH)through Network Meta-analysis,so as to obtain a more advantageous treatment plan and provide a certain reference value for clinical treatment of BPH.Methods: CNKI,Wan Fang Data,VIP,Sino Med,Cochrane Library,Pub Med and EMbase were searched by computer to collect data.Randomized controlled trial(RCT)of Chinese patent medicine for BPH were collected from January 2000 to March 2022.Note Express 3.5 software was used to screen the literature according to the established inclusion and exclusion criteria,and then the quality of the included literature was evaluated according to the Cochrane system evaluation manual.Revman 5.4 software and Stata 17.0 software were used to perform traditional Meta analysis and Network Meta-analysis on the relevant outcome indicators.Results: A total of 64 articles were included,with 6387 patients with BPH,including 3215 cases in the experimental group and 3172 cases in the control group,involving 12 kinds of Chinese patent medicines,namely Longbishu capsules,Qianlie Shutong capsules,Xia Liqi capsules,Jinkui Shenqi pills,Qianlieshu pills,Ningmitai capsules,Qianliexin capsules,Pule’an Tablets,Zegui Longshuang capsules,Weng Litong capsules,Qianlie Beixi capsules,and Qianlie Jindan tablets.1.In terms of total clinical effective rate,a total of 45 articles were included,involving 11 Chinese patent medicines.The results of traditional Meta-analysis showed that the total clinical effective rates of 11 Chinese patent medicines combined with conventional Western medicines were significantly better than those of conventional Western drugs,and the difference was statistically significant(P < 0.05).The results of Network Meta-analysis showed that Jinkui Shenqi pills combined with conventional western drug SUCRA had the largest value,which may have outstanding advantages in improving the overall clinical effect-ive rate.2.In terms of IPSS,a total of 57 articles were included,involving 12 Chinese patent medicines.The results of traditional Meta-analysis showed that the combination of Qianliexin capsules with conventional western drugs P=0.05 indicated that the difference was not significant compared with conventional western drugs.The IPSS of other Chinese patent medicines combined with conventional Western medicines was significantly lower than that of conventional Western medicines,and the difference was statistically significant(P<0.05).The results of Network Meta-analysis showed that the SUCRA value of Qianlie Jindan tablets combined with conventional western drugs was the largest,which may have outstanding advantages in subjectively improving patients’ urinary symptoms and reducing IPSS.3.In terms of QOL,a total of 23 articles were included,involving 12 Chinese patent medicines.The results of traditional meta-analysis showed that the QOL of Longbishu capsules,Xia Liqi capsules,Jinkui Shenqi pills,Qianlieshu pills,Ningmitai capsules,Qianliexin capsules,and Pule’an Tablets combined with conventional Western drugs were significantly lower than those of conventional Western drugs,and the differences were statistically significant(P<0.05).The QOL of other Chinese patent medicines combined with conventional Western medicines for the treatment of BPH was comparable to that of conventional Western medicines,and the difference was not statistically significant(P > 0.05).The results of the Network Meta-analysis showed that the SUCRA value of Xia Liqi capsules combined with conventional western drugs was the largest,which may have outstanding advantages in improving the quality of life of BPH patients.4.In terms of Qmax,a total of 54 articles were included,involving 12 Chinese patent medicines.The results of traditional Meta-analysis showed that the Qmax of 12 Chinese patent medicines combined with conventional Western drugs was significantly better than that of conventional Western drugs,and the difference was statistically significant(P<0.05).The results of Network Meta-analysis showed that Xia Liqi capsules combined with conventional western drugs had the largest SUCRA value,which may have outstanding advantages in improving Qmax in BPH patients.5.In terms of RU,a total of 52 articles were included,involving 12 Chinese patent medicines.The results of traditional Meta-analysis showed that the RU of BPH treated with Longbishu capsules,Qianlie Shutong capsules,Xia Liqi capsules,Jinkui Shenqi pills,Qianlieshu pills,Ningmitai capsules,Pule’an Tablets,Qianliexin capsules,Weng Litong capsules combined with conventional Western medicine were significantly lower than those of conventional Western drugs,and the difference was statistically significant(P< 0.05).The RU of other Chinese patent medicines combined with conventional Western medicines for the treatment of BPH was comparable to that of conventional Western medicine group,and the difference was not statistically significant(P>0.05).The results of the Network Meta-analysis showed that Zegui Longshuang capsules combined with conventional western drugs had the largest SUCRA value,which may have outstanding advantages in improving RU in BPH patients.6.In terms of PV,a total of 46 articles were included,involving 11 Chinese patent medicines.The results of traditional Meta-analysis showed that the PV of BPH treated by Longbishu capsules,Qianlie Shutong capsules,Jinkui Shenqi pills,Qianlieshu pills,Ningmitai capsules,Pule’an tablets,and Qianliexin capsules combined with conventional Western drugs were lower than those of conventional Western drugs,and the difference was statistically significant(P<0.05).The PV of other Chinese patent medicines combined with conventional western medicine group for the treatment of BPH was comparable to that of conventional western medicine group,and the difference was not statistically significant(P>0.05).The results of Network Meta-analysis showed that Pule’an Tablets combined with conventional western drugs had the largest SUCRA value,which may have outstanding advantages in reducing PV in BPH patients.7.In terms of adverse reactions,a total of 34 articles were included,involving 10 Chinese patent medicines.The results of traditional meta-analysis showed that the adverse reactions of Longbishu capsules combined with conventional Western drugs in the treatment of BPH were lower than those of conventional Western drugs,and the difference was statistically significant(P < 0.05).The adverse reactions of other Chinese patent medicines combined with conventional Western medicines in the treatment of BPH were comparable to those of conventional Western drugs,and the difference was not statistically significant(P>0.05).The results of the Network Meta-analysis showed that the SUCRA value of Longbishu capsules combined with conventional Western drugs was the largest,and it may be safer in the treatment of patients with BPH.Conclusions:1.Compared with conventional western medicine,Chinese patent medicine combined with conventional western medicine can significantly improve the clinical symptoms of BPH patients and enhance the clinical efficacy.2.For BPH patients,Jinkui Shenqi pills combined with conventional western medicine in improving the total clinical effective rate,Qianlie Jindan tablets combined with conventional western medicine in reducing IPSS,Xia Liqi capsules combined with conventional western medicine in improving the quality of life and improving Qmax,Zegui Longshuang capsules combined with conventional western medicine in reducing RU,Pule’an tablets combined with conventional western medicine in reducing PV have outstanding advantages.3.The safety profile of Longbishu capsules in combination with conventional Western drugs is better in the treatment of patients with BPH. |
PDF Full Text Request